Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.47 |
| ▸ | CTSG | P08311 | 3/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.47 |
| ▸ | CMA1 | P23946 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9576675 | 0.81 | MMP2 (0.61) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL7066806 | 0.81 | MDM2 (0.52) | CES2CES1PRSS1CTSGCTRB1 | |
| Hydrochloric Acid SCHEMBL9449101 | 0.80 | CES2 (0.47) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL30979218 | 0.79 | CES2 (0.53) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL6424289 | 0.79 | CES2 (0.50) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL637814 | 0.79 | GPR84 (0.53) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL10456426 | 0.79 | CES2 (0.53) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL9352547 | 0.79 | CES2 (0.50) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL29117316 | 0.79 | MMP2 (0.63) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL27836181 | 0.79 | CES2 (0.53) | CES2CES1PRSS1CTSGCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030330-B2 | Benzothiophenes, formulations containing same, and methods | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100255106-A1 | BENZOTHIOPHENES, FORMULATIONS CONTAINING SAME, AND METHODS | ARBUTHNOT GORDON NELSON | 2010-10-07 | — | — | US | disclosed |
| US-20050239840-A1 | Benzothiophenes, formulations containing same, and methods | ARBUTHNOT GORDON N | 2005-10-27 | — | — | US | disclosed |
| US-6894064-B2 | Benzothiophenes, formulations containing same, and methods | ELI LILLY AND COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| US-6797719-B2 | OSTEOPOROSIS; ANTILIPEMIC AGENTS; ANTICANCER AGENTS | ELI LILLY AND COMPANY | 2004-09-28 | — | — | US | disclosed |
| US-20040180932-A1 | Benzothiophenes, formulations containing same, and methods | ARBUTHNOT GORDON NELSON (US) | 2004-09-16 | — | — | US | disclosed |
| US-20030187025-A1 | Benzothiophenes, formulations containing same, and methods | ARBUTHNOT GORDON NELSON (US) | 2003-10-02 | — | — | US | disclosed |
| EP-0832891-B1 | Dihydrobenzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods | LILLY CO ELI (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0832890-B1 | Benzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods | LILLY CO ELI (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020173645-A1 | Non-solvated crystalline 6-hydroxy-2- (4-hydroxyphenyl) -3- [4- (2-piperidinoethoxy) benzoyl] benzo [b] thiophene hydrochloride | LUKE WAYNE DOUGLAS (US) | 2002-11-21 | — | — | US | disclosed |
| US-6133458-A | FOR INHIBITING BONE LOSS OR BONE RESORPTION, PARTICULARLY OSTEOPOROSIS, CARDIOVASCULAR-RELATED PATHOLOGICAL CONDITIONS INCLUDING HYPERLIPIDEMIA AND RELATED CARDIOVASCULAR PATHOLOGIES, AND ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| US-6008377-A | ACYLATING A N-DISUBSTITUED-PHENYLOXYETHYLAMINE CHLORO OR BROMO SALT WITH A BENZOTHIOPHENE DERIVATIVE IN PRESENCE OF TRIBOROCHLORIDE OR BROMIDE, DEALKYLATING ONE OR MORE PHENOLIC GROUP OF THE PRODUCT WITH ADDITIONAL BOROHALIDE | ELI LILLY AND COMPANY (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0888331-A1 | SYNTHESIS OF 3-[4-(2-AMINOETHOXY)-BENZOYL]-2-ARYL-6-HYDROXY-BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5856341-A | INHIBITING BONE LOSS OR BONE RESORPTION, PARTICULARLY OSTEOPOROSIS, CARDIOVASCULAR-RELATED PATHOLOGICAL CONDITIONS INCLUDING HYPERLIPIDEMIA, ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| US-5834488-A | INHIBIT BONE LOSS OR BONE RESORPTION, LOWER SERUM CHOLESTEROL LEVELS, INHIBIT ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0832891-A1 | Dihydrobenzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0832890-A1 | Benzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5731327-A | Synthesis of 3- 4-(2-aminoethoxy)benzoyl!-2-aryl-6-hydroxybenzo b!thiophenes | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997034888-A1 | SYNTHESIS OF 3-[4-(2-AMINOETHOXY)-BENZOYL]-2-ARYL-6-HYDROXY-BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1997-09-25 | — | — | WO | disclosed |
| US-5629425-A | NONSTEROIDAL ANTIESTROGEN | ELI LILLY AND COMPANY (US) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239840-A1 | Benzothiophenes, formulations containing same, and methods | BRCA1, CYP19A1, CYP46A1 | CES2 3987/4885CES1 859/4885PRSS1 676/4885 |
| US-20040180932-A1 | Benzothiophenes, formulations containing same, and methods | BRCA1, CYP46A1, SULT1A1 | CES2 4088/4885CES1 586/4885PRSS1 509/4885 |
| US-20030187025-A1 | Benzothiophenes, formulations containing same, and methods | BRCA1, CYP46A1, SULT1A1 | CES2 4088/4885CES1 586/4885PRSS1 509/4885 |
| US-20100255106-A1 | BENZOTHIOPHENES, FORMULATIONS CONTAINING SAME, AND METHODS | BRCA1, CYP19A1, CYP46A1 | CES2 3987/4885CES1 859/4885PRSS1 676/4885 |
| US-20020173645-A1 | Non-solvated crystalline 6-hydroxy-2- (4-hydroxyphenyl) -3- [4- (2-piperidinoethoxy) benzoyl] benzo [b] thiophene hydrochloride | HTR3B, HTR3C, HTR2B | CES2 588/4885CES1 3767/4885PRSS1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.